Anti-metapneumovirus monoclonal antibody - MedImmune

Drug Profile

Anti-metapneumovirus monoclonal antibody - MedImmune

Alternative Names: Anti-hMPV MAb - MediImmune; mAb-338

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroNovative
  • Developer MedImmune
  • Class Monoclonal antibodies; Viral vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Metapneumovirus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Metapneumovirus-infections in USA (IM, Injection)
  • 15 Sep 2009 Pharmacodynamics data from a preclinical trial in human metapneumovirus presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
  • 18 Sep 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2007) added to the Viral Infections pharmacodynamics and immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top